Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 06, 2026
Why Is Figma (FIG) Stock Down -19.43% Today?

Why Is Figma (FIG) Stock Down -19.43% Today?

Key Takeaways

  • Figma shares plummeted approximately 19.4% in Thursday's trading session, sliding from a prior close of $28.15 to around $22.68 intraday, after the company's Q2 earnings report triggered a sharp sell-off.
  • The primary catalyst was a surge in AI-related spending that nearly doubled operating expenses year over year and swung the company to a GAAP operating loss, overshadowing strong revenue growth and an earnings beat.
  • Annual operating income guidance disappointed, with the midpoint of the $125–$135 million range coming in below Wall Street consensus, fueling concerns about profitability trajectory.
  • Broader software-sector weakness compounded the move, with peers including Adobe, Salesforce, ServiceNow, and Intuit also trading lower in sympathy.
  • Elevated trading volume — more than double the daily average during Wednesday's regular session — signaled intense investor repositioning around the stock.

Opening Summary

Shares of FIG, the AI-powered collaborative design platform company Figma, Inc., tumbled roughly 19.4% on Thursday after the company's second-quarter earnings report — released after Wednesday's close — ignited a fierce sell-off. The stock, which closed Wednesday's regular session at $28.15 following a 3.8% gain, cratered to approximately $22.68 in Thursday trading. Despite posting revenue of $370.1 million that surged 48% year over year and adjusted earnings per share of $0.08 that doubled analyst estimates, investors fixated on soaring AI investment costs, a GAAP operating loss, and annual profit guidance that fell shy of expectations.

Q2 Earnings: A Beat-and-Raise Quarter That Wasn't Enough

At first glance, Figma's second-quarter results appeared robust. Revenue climbed 48% year over year to $370.1 million, comfortably surpassing the $351.6 million consensus estimate. Adjusted earnings per share of $0.08 doubled the $0.04 Wall Street had projected. The company also raised its full-year revenue guidance by roughly $40 million to a range of $1.463 billion to $1.467 billion, well above the prior forecast and ahead of analyst expectations.

Yet the market seized on what lay beneath the headline numbers. GAAP operating expenses nearly doubled to $426.9 million from the year-ago period, driven largely by a more-than-doubling of research and development costs to $167.3 million. This spending surge pushed the company to a GAAP operating loss of $117.3 million — a sharp reversal from a modest $2 million operating profit a year earlier. Stock-based compensation alone totaled $147.6 million. Free cash flow margin contracted to 14% from 24% a year ago, intensifying concerns that Figma's AI ambitions are coming at a steep and growing cost.

Profit Outlook Disappoints

Adding fuel to the sell-off, Figma's full-year adjusted operating income guidance of $125 million to $135 million landed at the lower end of the $133.2 million consensus estimate. For a stock that had rallied approximately 13.7% in the week leading into earnings — reflecting elevated expectations — the lack of a meaningful profitability upgrade was treated as a disappointment. Third-quarter revenue guidance of $373 million to $375 million, while slightly above consensus, was similarly not viewed as a significant upside surprise. The combination of robust top-line growth with underwhelming profit visibility proved toxic for shares.

AI Investment Anxiety Takes Center Stage

Figma has aggressively positioned itself as an AI-native design and product development platform, integrating AI features across its suite — from Figma Make to AI Credits, a consumption-based monetization model introduced in March. While management highlighted that over 50% of paid customers with annual recurring revenue above $10,000 now use the Figma Agent AI tool weekly, and that net dollar retention held strong at 136%, investors appear increasingly skeptical that AI spending will translate into durable margin expansion anytime soon.

CFO Praveer Melwani noted on the earnings call that the company is "hiring fewer people today than we originally had planned" because AI tools are augmenting existing teams. Yet for the market, the immediate math of doubling R&D expenditures overwhelmed the longer-term efficiency narrative. The episode echoes broader market anxiety across the software sector about whether heavy AI investments will generate commensurate returns or simply compress margins indefinitely.

Market Context and Trading Activity

The sell-off in FIG did not occur in isolation. Software stocks broadly came under pressure, with ADBE (Adobe), CRM (Salesforce), NOW (ServiceNow), and INTU (Intuit) all declining in sympathy as Figma's results reinforced sector-wide concerns about AI cost structures. Wednesday's regular session had already seen elevated volume of approximately 45.7 million shares — more than double the 20-day average of roughly 20 million — as traders positioned ahead of the report.

The magnitude of Thursday's decline pushed Figma shares deep into negative territory for the year, extending a drawdown that has already seen the stock fall more than 75% from its post-IPO peak. The stock now trades closer to its 52-week low of $16.60 than to its 52-week high, reflecting the persistent pressure that AI-disruption fears have exerted on design-software valuations throughout 2026.

What Comes Next for FIG

Investor attention now turns to whether Figma can demonstrate that its AI spending is laying the groundwork for reaccelerating profitability rather than simply inflating the cost base. Key metrics to watch in the coming quarters include the trajectory of AI Credits adoption, net dollar retention trends, and operating margin progression. The competitive landscape also remains a focal point, with AI-native design tools from major platform players continuing to emerge. Figma's ability to convert its collaboration-platform advantages into sustainable earnings growth will likely determine whether the post-earnings sell-off marks a capitulation bottom or merely another leg lower in a difficult year for the stock.

Trending AI Robots

For traders seeking to navigate volatile market conditions with data-driven strategies, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron hosts hundreds of AI trading bots covering thousands of tickers across diverse strategies, timeframes, and performance metrics, but only the strongest performers under current market conditions are featured in this dedicated section. Each bot varies by approach — from swing trading to trend following — allowing users to identify strategies aligned with their goals. Explore the Trending AI Robots page to see which algorithms are delivering standout results right now.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: FIG

FIG in +12.96% Uptrend, growing for three consecutive days on August 05, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where FIG advanced for three days, in of 224 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 28, 2026. You may want to consider a long position or call options on FIG as a result. In of 65 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for FIG just turned positive on July 28, 2026. Looking at past instances where FIG's MACD turned positive, the stock continued to rise in of 37 cases over the following month. The odds of a continued upward trend are .

FIG moved above its 50-day moving average on July 27, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for FIG crossed bullishly above the 50-day moving average on July 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 107 cases where FIG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FIG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

FIG broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. FIG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FIG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.204) is normal, around the industry mean (27.954). P/E Ratio (0.000) is within average values for comparable stocks, (81.868). FIG's Projected Growth (PEG Ratio) (7.952) is very high in comparison to the industry average of (1.680). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. P/S Ratio (12.755) is also within normal values, averaging (52.021).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Shopify Inc (NASDAQ:SHOP), Salesforce (NYSE:CRM), Uber Technologies (NYSE:UBER), ServiceNow Inc. (NYSE:NOW), Adobe (NASDAQ:ADBE), Datadog (NASDAQ:DDOG), Intuit (NASDAQ:INTU), Autodesk (NASDAQ:ADSK), Workday (NASDAQ:WDAY), Zoom Communications Inc (NASDAQ:ZM).

Industry description

Packaged software comprises multiple software programs bundled together and sold as a group. For example, Microsoft Office includes multiple applications such as Excel, Word, and PowerPoint. In some cases, buying a bundled product is cheaper than purchasing each item individually[s20] . Microsoft Corporation, Oracle Corp. and Adobe are some major American packaged software makers.

Market Cap

The average market capitalization across the Packaged Software Industry is 10.01B. The market cap for tickers in the group ranges from 291 to 222.3B. SAP holds the highest valuation in this group at 222.3B. The lowest valued company is BLGI at 291.

High and low price notable news

The average weekly price growth across all stocks in the Packaged Software Industry was 7%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 6%. YXT experienced the highest price growth at 686%, while YAAS experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Packaged Software Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was 47% and the average quarterly volume growth was -24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 77
Price Growth Rating: 57
SMR Rating: 78
Profit Risk Rating: 94
Seasonality Score: -5 (-100 ... +100)
View a ticker or compare two or three
FIG
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry PackagedSoftware

Profile
Details
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.